ReviewViruses2018
Potential Application of the CRISPR/Cas9 System against Herpesvirus Infections.
Review in Viruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Precision engineering of human cytomegalovirus without BAC constraints: a Sendai virus-delivered CRISPR/Cas9 approach.The Journal of general virology · 2025Article
- Harnessing CRISPR technology for viral therapeutics and vaccines: from preclinical studies to clinical applications.Virus research · 2024Review
- Recombinant Marek's disease virus expressing VP1 and VP2 proteins provides robust immune protection against chicken infectious anemia virus.Frontiers in microbiology · 2024Article
- Herpesvirus Diseases in Humans and Animals: Recent Developments, Challenges, and Charting Future Paths.Pathogens (Basel, Switzerland) · 2023Article
- Current Perspectives on the Management of Herpesvirus Infections in Solid Organ Transplant Recipients.Viruses · 2023Review
- Point-of-Care Testing for Infectious Diseases Based on Class 2 CRISPR/Cas Technology.Diagnostics (Basel, Switzerland) · 2023Review
- Review
- Challenges, Recent Advances and Perspectives in the Treatment of Human Cytomegalovirus Infections.Tropical medicine and infectious disease · 2022Review
- Article
- Exploring nano-enabled CRISPR-Cas-powered strategies for efficient diagnostics and treatment of infectious diseases.Journal of nanostructure in chemistry · 2022Review
- Methods for the Manipulation of Herpesvirus Genome and the Application to Marek's Disease Virus Research.Microorganisms · 2021Review
- Therapeutic Genome Editing and In Vivo Delivery.The AAPS journal · 2021Review
- Review
- Review
- Targeting the Kaposi's sarcoma-associated herpesvirus genome with the CRISPR-Cas9 platform in latently infected cells.Virology journal · 2021Article
- Nutraceutical Curcumin with Promising Protection against Herpesvirus Infections and Their Associated Inflammation: Mechanisms and Pathways.Microorganisms · 2021Review
- Insight for Immunotherapy of HCMV Infection.International journal of biological sciences · 2021Review
- Functional Identification of theFrontiers in microbiology · 2021Article
- RNA-guided gene editing of the murine gammaherpesvirus 68 genome reduces infectious virus production.PloS one · 2021Article
- CRISPR-Csy4-Mediated Editing of Rotavirus Double-Stranded RNA Genome.Cell reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The CRISPR/Cas9 system has been applied in the genome editing and disruption of latent infections for herpesviruses such as the herpes simplex virus, Epstein⁻Barr virus, cytomegalovirus, and Kaposi's sarcoma-associated herpesvirus. CRISPR/Cas9-directed mutagenesis can introduce similar types of mutations to the viral genome as can bacterial artificial chromosome recombination engineering, which maintains and reconstitutes the viral genome successfully. The cleavage mediated by CRISPR/Cas9 enables the manipulation of disease-associated viral strains with unprecedented efficiency and precision. Additionally, current therapies for herpesvirus productive and latent infections are limited in efficacy and cannot eradicate viruses. CRISPR/Cas9 is potentially adapted for antiviral treatment by specifically targeting viral genomes during latent infections. This review, which focuses on recently published progress, suggests that the CRISPR/Cas9 system is not only a useful tool for basic virology research, but also a promising strategy for the control and prevention of herpesvirus latent infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.